Forest closes in on Aptalis for $3B

Forest Laboratories (FRX) is reportedly close to agreeing to buy Aptalis Holdings from private equity firm TPG Capital for $3B, with an announcement about the deal possible today.

Forest has been looking to buy in treatments due to patent expirations on its own blockbuster drugs, such as the antidepressant Lexapro. Aptalis' therapies include those for cystic fibrosis and gastrointestinal disorders; the latter would complement Forest's Linzess.

Aptalis filed for an IPO in late December in case TPG would be unable to sell the company.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs